GeoVax Labs, Inc.

What they do

GeoVax develops human vaccines and immunotherapies using proprietary platforms. Its lead near-term program is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox, smallpox and other poxviruses being advanced under an expedited European regulatory pathway. Its lead oncology program is Gedeptin, an oncolytic gene-directed therapy that completed a Phase 1/2 trial in advanced head and neck cancer. It also develops GEO-CM04S1, a multi-antigen COVID-19 vaccine in Phase 2 trials.

Revenue drivers

• Government contract revenues (BARDA) — Revenue in recent periods came entirely from a contract with the Biomedical Advanced Research and Development Authority; the company reported $852,282 in Q2 2025 and $2,489,145 for the six months then ended, and has had no product revenue to date.
• Grants and collaborations — The 10-K states revenues from government grants and other collaborations have not generated sufficient cash flows to cover operating expenses.
• GEO-MVA (pre-commercial) — No revenue; the company describes GEO-MVA as its most near-term opportunity to achieve regulatory approval and potential commercialization.
• Gedeptin and GEO-CM04S1 (clinical stage) — No revenue; both remain in clinical development, with Gedeptin Phase 2 planned for H1 2027 and GEO-CM04S1 in two Phase 2 trials.

Recent performance

Second quarter 2026 net loss was $4,426,578, or $0.97 per share, versus $5,369,783, or $8.74 per share, in Q2 2025. Six-month 2026 net loss was $9,688,499, or $2.94 per share, compared with $10,727,434, or $19.72 per share, a year earlier. Quarterly revenue was $0.00 for the four most recent quarters reported (September 2025 through June 2026). At June 30, 2026, total assets were $4.6 million, total liabilities $2.9 million, stockholders' equity $1.8 million and cash and cash equivalents $3.1 million. Full-year 2025 revenue was $2.5 million against a $21.5 million net loss.

Strategy

The company's primary near-term priority is advancing GEO-MVA toward a pivotal Phase 3 trial, with initiation planned for the second half of 2026 and operational activities underway for an expected fourth-quarter 2026 start of a pivotal immunobridging study under an expedited pathway established through Scientific Advice with the European Medicines Agency. It is also advancing the AGE1 continuous cell-line manufacturing platform for future commercial-scale MVA production and engaging government, public health and biodefense stakeholders on orthopoxvirus supply needs. In oncology, it plans a Phase 2 trial of Gedeptin plus an immune checkpoint inhibitor in squamous cell head and neck cancer in the first half of 2027. The company states it is prioritizing disciplined capital allocation across these lead programs and pursuing regulatory approval and commercialization through internal development and selective licensing or partnerships.

Risks

• History of operating losses — The company reported a net loss of approximately $21.5 million for 2025 and expects cumulative losses to increase as development expands, with no product revenue to date.
• No product revenue — Recent quarterly revenue has been $0.00, and the 10-K states government grants and collaborations have not generated sufficient cash flows to cover operating expenses.
• Thin cash and equity position — At June 30, 2026, cash and cash equivalents were $3.1 million against total liabilities of $2.9 million and stockholders' equity of $1.8 million, so further financing will likely be needed.
• Nasdaq listing-rule failures — The company disclosed delisting notices or listing-rule failures in 8-K filings on July 10, 2026 and August 28, 2026.

Outlook

Management says its priorities are completing activities to initiate the pivotal GEO-MVA immunobridging study, which it expects to start in the fourth quarter of 2026 under its expedited European regulatory pathway, and maintaining disciplined capital allocation. It also points to engagement with government and international stakeholders regarding future orthopoxvirus vaccine procurement. For Gedeptin, it plans to initiate a Phase 2 combination trial with an immune checkpoint inhibitor in the first half of 2027. GEO-CM04S1 data readouts were anticipated in the first half of 2026 for the healthy-adult booster trial.